Who Founded Amgen?

Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA. The driving force behind the formation was William K. (Bill) Bowes, a prominent San Francisco venture capitalist, alongside colleagues from the Bay Area. They recruited George Rathmann, a physical chemist and executive at Abbott Laboratories, to serve as the founding CEO. Rathmann was the true architect of Amgen's culture and success. While other early biotech companies (like Genentech) focused heavily on high-profile, academic research that often failed to translate into profitable products, Rathmann focused Amgen on applied science, specifically, using recombinant DNA to solve unmet medical needs that could generate significant revenue. He assembled a well-known team of effective, young scientists and established a collaborative, egalitarian culture in Thousand Oaks, California, far away from the intense academic rivalries of Boston and San Francisco. The foundational breakthrough for the company occurred in 1983 when a young Taiwanese-born researcher named Fu-Kuen Lin cloned the human gene for erythropoietin (EPO), a protein that stimulates the production of red blood cells. This discovery was considered almost impossible by rival companies due to the sheer complexity of the genome. Lin's discovery led directly to the creation of Epogen, a drug that cured the horrific anemia suffered by dialysis patients. Approved by the FDA in 1989, Epogen became one of the most successful and profitable drugs in the history of medicine, single-handedly transforming Amgen from a scrappy, cash-starved startup into the financial leader of the global biotechnology industry. (Exact birth year remains publicly undisclosed).

William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation. His approach to building Amgen differed from most biotech founding stories in that he began with the commercial and organizational framework, experienced management, sufficient capital, a culture that valued both science and business, and then recruited the scientific leadership rather than the other way around. This top-down approach to company formation, unusual in an industry dominated by scientist-founders, proved prescient: Amgen's early organizational discipline helped it survive the financially devastating pre-commercial years that destroyed many of its contemporaries. Bowes remained on Amgen's board for many years after the company's commercial launch, providing governance continuity during the company's critical growth phase. His legacy in the biotech industry extends beyond Amgen, he was an early investor in multiple pioneering biotechs and helped establish the venture capital model for funding science-based startups that became the template for Silicon Valley health technology investing. (Exact birth year remains publicly undisclosed).